drugset / Trial / NCT07038200
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
Timeline
- Start
- 2025-06-10
- Primary completion
- 2028-05
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AOC 1020 | Unknown | — | Intravenous |